• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?

    Simply Wall St·06/29/2026 15:20:49
    Listen to the news

    Adaptive Biotechnologies (ADPT) is back in focus after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses, alongside completing a $300 million zero coupon convertible notes offering.

    See our latest analysis for Adaptive Biotechnologies.

    These separation plans and the recent convertible notes offering come on the back of strong momentum in Adaptive Biotechnologies' stock, with a 30 day share price return of 38.35% and a 1 year total shareholder return of 79.91%, although the 5 year total shareholder return is down 46.68%, indicating a mixed longer term picture.

    If you are looking beyond Adaptive Biotechnologies for other ways to position around healthcare and AI trends, it may be worth scanning 40 healthcare AI stocks

    With Adaptive Biotechnologies now pursuing a business separation and fresh funding via zero coupon convertible notes, yet trading slightly above one analyst price target and an estimated intrinsic value, the key question is: is there still a buying opportunity here, or is the market already pricing in future growth?

    Most Popular Narrative: 4.1% Overvalued

    With Adaptive Biotechnologies' last close at $20.96 versus a most-followed fair value of $20.14, the narrative now frames the stock as slightly ahead of that central estimate while hinging heavily on the MRD business.

    Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

    Read the complete narrative.

    Curious what underpins that $20.14 fair value for Adaptive Biotechnologies? The narrative leans on brisk revenue expansion, a future profit margin reset, and a rich earnings multiple that would usually be reserved for higher growth leaders. The full story connects those assumptions into one tight earnings path and a valuation bridge that investors will want to see in detail.

    Result: Fair Value of $20.14 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear pressure points, including continued losses at Adaptive Biotechnologies and reliance on a handful of key partnerships that could disrupt the current fair value story.

    Find out about the key risks to this Adaptive Biotechnologies narrative.

    Next Steps

    With sentiment on Adaptive Biotechnologies split between concern and optimism, it makes sense to move quickly and stress test the details for yourself, starting with the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Adaptive Biotechnologies?

    If you are serious about building a stronger portfolio, do not stop at Adaptive Biotechnologies. Use focused stock lists to uncover ideas that fit your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.